441O A phase I clinical trial on the intracranial administration of autologous CD1c(BDCA-1)+ /CD141(BDCA-3)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and nivolumab (NIVO) in patients with recurrent high-grade glioma (rHGG).
Saved in:
| Title: | 441O A phase I clinical trial on the intracranial administration of autologous CD1c(BDCA-1)+ /CD141(BDCA-3)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and nivolumab (NIVO) in patients with recurrent high-grade glioma (rHGG). |
|---|---|
| Authors: | Neyns, B.1 (AUTHOR), Dirven, I.1 (AUTHOR), Lescrauwaet, L.2 (AUTHOR), Cammaert, M.1 (AUTHOR), Geens, W.2 (AUTHOR), Geeraerts, X.1 (AUTHOR), Stevens, L.1 (AUTHOR), Brock, S.3 (AUTHOR), Kockx, M.4 (AUTHOR), Everaert, H.5 (AUTHOR), Binst, A-M. Van6 (AUTHOR), Tuyaerts, S.1 (AUTHOR), Duerinck, J.7 (AUTHOR) |
| Source: | Annals of Oncology. 2024 Supplement 2, Vol. 35, pS406-S407. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2024.08.511 |
